Fujirebio Diagnostics Inc., Pacific Northwest Research Institute, Randox Laboratories Ltd. deal

Fujirebio received global rights from Pacific Northwest to develop two ovarian markers - mesothelin and HE4. Fujirebio intends to combine the two markers with CA125II, a serum-based assay, to develop improved diagnostics to detect early stage ovarian cancer. ...